Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz vs Metvix in Non-aggressive BCC
NCT02144077Phase 3Completed
- Sponsor
- Biofrontera
- Start
- Jan 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of aminolevulinic acid 10% gel in basal cell carcinoma (BCC) (2 arms), sponsored by Biofrontera. Primary endpoint: Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT. Started Jan 2014; status: completed.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02144077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144077.